The Cancerous Plasma Cell
Multiple Myeloma and Related Malignancies
- 1st Edition - January 1, 2027
- Latest edition
- Editors: Asher Chanan-Khan, Sikander Ailawadhi
- Language: English
The Cancerous Plasma Cell: Multiple Myeloma and Related Plasma Cell Disorders is a comprehensive academic book that offers an authoritative exploration of one of the most comple… Read more
Description
Description
The Cancerous Plasma Cell: Multiple Myeloma and Related Plasma Cell Disorders is a comprehensive academic book that offers an authoritative exploration of one of the most complex hematologic malignancies. Designed for a multidisciplinary audience, it integrates the latest scientific and clinical advancements to provide a holistic understanding of multiple myeloma and related disorders. The book delves into cutting-edge developments in diagnostics, genomics, and therapeutic strategies, including targeted, cellular, and immune-based treatments. It presents evidence-based insights into disease biology, staging, and personalized care approaches, while also incorporating patient and caregiver perspectives to emphasize the importance of supportive care and quality of life. This resource equips clinicians, researchers, and students with a unified, up-to-date reference that bridges research and practice. By consolidating rapidly evolving knowledge into a single, peer-reviewed volume, it promotes consistent, data-driven decision-making and fosters improved patient outcomes across diverse healthcare settings.
Key features
Key features
- Synthesizes the latest advancements in diagnostics, genomics, and therapeutic strategies, offering a comprehensive and up-to-date reference on multiple myeloma and related plasma cell disorders
- Emphasizes evidence-based, patient-centered care by combining scientific rigor with real-world insights, including patient and caregiver experiences, to support holistic and personalized treatment approaches
- Integrates multidisciplinary perspectives from leading experts across clinical, research, and educational domains, ensuring a well-rounded and authoritative academic resource
Readership
Readership
Medical professionals involved in the diagnosis, treatment, and management of plasma cell disorders, especially Medical oncologists Academic and clinical researchers in cancer research and translational medicine
Table of contents
Table of contents
SECTION A: FUNDAMENTALS OF MULTIPLE MYELOMA
1. Introduction to the Book
2. The Plasma Cell
3. Multiple Myeloma Overview
4. Risk Factors for Various Plasma Cell Malignancies
5. Race and Multiple Myeloma
6. Genetics and Plasma Cell Cancers
7. Diagnosing Multiple Myeloma
8. Clinical Staging and Assessment of Response in Multiple Myeloma
9. Monoclonal Gammopathy of Unknown Significance (MGUS)
10. Smoldering Multiple Myeloma
11. Overview on the Clinical Presentation of Multiple Myeloma
SECTION B: TREATING MULTIPLE MYELOMA & OTHER PLASMA CELL CANCERS
12. Overall Approach to Treatment of Multiple Myeloma
13. Management of Treatment-Naïve Multiple Myeloma Patient
14. Management of Relapsed Multiple Myeloma
15. Evolution of the Role of High-Dose Chemotherapy and Autologous Stem Cell Transplant
16. Therapeutic Agents in Multiple Myeloma
17. Cytotoxic Chemotherapies in Multiple Myeloma
18. Biologics in Multiple Myeloma
19. Steroids in Multiple Myeloma
20. IMIDs in Multiple Myeloma
21. Proteasome in Multiple Myeloma
22. CART in Multiple Myeloma
23. BCL2 Inhibition in Multiple Myeloma
24. Investigational Molecules in Pipeline
25. Radiation Treatment in Multiple Myeloma
26. Management of Multiple Myeloma in Resource-Limited Countries
SECTION C: BONE DISEASE IN MULTIPLE MYELOMA
27. The Biology of Bone Disease in Multiple Myeloma
28. Clinical Presentation and Evaluation of Bone Disease
29. Bisphosphonates in the Treatment of Multiple Myeloma
30. Monoclonal Antibodies in Treatment of Bone Disease
31. Vertebral Body Stabilization Procedures
32. Management of Pathological Bone Fracture
SECTION D: SPECIAL CLINICAL CONDITIONS IN PLASMA CELL MALIGNANCIES
33. Solitary Plasmacytoma
34. POEMS Syndrome
35. Neurologic Complications in Multiple Myeloma
36. Renal Disease in Multiple Myeloma
37. IgM Multiple Myeloma
38. Management of Plasma Cell Leukemia
39. Second Primary Cancers
SECTION E: AMYLOIDOSIS
40. Overview and Biology of Amyloidosis
41. Clinical Presentation and Diagnosis of Amyloidosis
42. Therapeutic Options in Amyloidosis
43. Role of High-Dose Chemotherapy and Autologous Stem Cell Transplant
44. Managing the Complications of Amyloidosis
45. Promising New Agents for Amyloidosis
SECTION F: WALDENSTRÖM MACROGLOBULINEMIA
46. Overview and Biology of Waldenström Macroglobulinemia
47. Clinical Presentation of Waldenström Macroglobulinemia
48. Therapeutic Approaches to Waldenström Macroglobulinemia
49. BTK Inhibitors in the Treatment of Waldenström Macroglobulinemia
50. BCL2 Inhibitors in the Treatment of Waldenström Macroglobulinemia
SECTION G: SOCIAL & SUPPORTIVE CARE
51. Pain Management
52. Managing Venous Thromboembolism
53. Infectious Complications in Plasma Cell Cancers
54. Role of Caregivers in Plasma Cell Disorders
55. Economic Burden and Financial Toxicities
56. Role of Expert and Second Opinions
57. Social and Clinical Impact of Myeloma Support Group
58. Clinical Trials and Analyzing Enrollment Challenges
59. Diet and Multiple Myeloma
60. Being a Patient with Multiple Myeloma
61. Being a Caregiver of a Multiple Myeloma Patient
62. Patient Advocate Societies and Their Impact on Multiple Myeloma Research and Patient Care
1. Introduction to the Book
2. The Plasma Cell
3. Multiple Myeloma Overview
4. Risk Factors for Various Plasma Cell Malignancies
5. Race and Multiple Myeloma
6. Genetics and Plasma Cell Cancers
7. Diagnosing Multiple Myeloma
8. Clinical Staging and Assessment of Response in Multiple Myeloma
9. Monoclonal Gammopathy of Unknown Significance (MGUS)
10. Smoldering Multiple Myeloma
11. Overview on the Clinical Presentation of Multiple Myeloma
SECTION B: TREATING MULTIPLE MYELOMA & OTHER PLASMA CELL CANCERS
12. Overall Approach to Treatment of Multiple Myeloma
13. Management of Treatment-Naïve Multiple Myeloma Patient
14. Management of Relapsed Multiple Myeloma
15. Evolution of the Role of High-Dose Chemotherapy and Autologous Stem Cell Transplant
16. Therapeutic Agents in Multiple Myeloma
17. Cytotoxic Chemotherapies in Multiple Myeloma
18. Biologics in Multiple Myeloma
19. Steroids in Multiple Myeloma
20. IMIDs in Multiple Myeloma
21. Proteasome in Multiple Myeloma
22. CART in Multiple Myeloma
23. BCL2 Inhibition in Multiple Myeloma
24. Investigational Molecules in Pipeline
25. Radiation Treatment in Multiple Myeloma
26. Management of Multiple Myeloma in Resource-Limited Countries
SECTION C: BONE DISEASE IN MULTIPLE MYELOMA
27. The Biology of Bone Disease in Multiple Myeloma
28. Clinical Presentation and Evaluation of Bone Disease
29. Bisphosphonates in the Treatment of Multiple Myeloma
30. Monoclonal Antibodies in Treatment of Bone Disease
31. Vertebral Body Stabilization Procedures
32. Management of Pathological Bone Fracture
SECTION D: SPECIAL CLINICAL CONDITIONS IN PLASMA CELL MALIGNANCIES
33. Solitary Plasmacytoma
34. POEMS Syndrome
35. Neurologic Complications in Multiple Myeloma
36. Renal Disease in Multiple Myeloma
37. IgM Multiple Myeloma
38. Management of Plasma Cell Leukemia
39. Second Primary Cancers
SECTION E: AMYLOIDOSIS
40. Overview and Biology of Amyloidosis
41. Clinical Presentation and Diagnosis of Amyloidosis
42. Therapeutic Options in Amyloidosis
43. Role of High-Dose Chemotherapy and Autologous Stem Cell Transplant
44. Managing the Complications of Amyloidosis
45. Promising New Agents for Amyloidosis
SECTION F: WALDENSTRÖM MACROGLOBULINEMIA
46. Overview and Biology of Waldenström Macroglobulinemia
47. Clinical Presentation of Waldenström Macroglobulinemia
48. Therapeutic Approaches to Waldenström Macroglobulinemia
49. BTK Inhibitors in the Treatment of Waldenström Macroglobulinemia
50. BCL2 Inhibitors in the Treatment of Waldenström Macroglobulinemia
SECTION G: SOCIAL & SUPPORTIVE CARE
51. Pain Management
52. Managing Venous Thromboembolism
53. Infectious Complications in Plasma Cell Cancers
54. Role of Caregivers in Plasma Cell Disorders
55. Economic Burden and Financial Toxicities
56. Role of Expert and Second Opinions
57. Social and Clinical Impact of Myeloma Support Group
58. Clinical Trials and Analyzing Enrollment Challenges
59. Diet and Multiple Myeloma
60. Being a Patient with Multiple Myeloma
61. Being a Caregiver of a Multiple Myeloma Patient
62. Patient Advocate Societies and Their Impact on Multiple Myeloma Research and Patient Care
Product details
Product details
- Edition: 1
- Latest edition
- Published: January 1, 2027
- Language: English
About the editors
About the editors
AC
Asher Chanan-Khan
Asher A. Chanan-Khan, M.D., is dedicated to developing treatments for CLL, Waldenstrom macroglobulinemia, and multiple myeloma. He collaborates closely with clinical and research teams to improve patient quality of life. With over a decade of experience in therapeutics and laboratory research, his expertise lies in preclinical target validation and early-phase drug evaluation. Dr. Chanan-Khan has contributed to the development of immunomodulating drugs, including thalidomide analogs and lenalidomide, which he helped introduce for CLL. He is actively involved in phase 1 and 2 trials of promising agents, including proteasome inhibitors like bortezomib and carfilzomib, and monoclonal antibodies for multiple myeloma. As principal investigator on numerous clinical trials, he has published over 200 articles. He also holds leadership roles on various Mayo Clinic, national, and international committees related to these diseases.
Affiliations and expertise
Mayo Clinic, USASA
Sikander Ailawadhi
Dr. Sikander Ailawadhi is a board-certified oncologist specializing in hematologic malignancies at the Mayo Clinic in Jacksonville, Florida. He is a key member of the Hematology Department and the CAR-T Cell Therapy Program. Dr. Ailawadhi’s clinical focus includes the treatment of multiple myeloma, Waldenstrom’s macroglobulinemia, and chronic leukemias such as CLL and CML.
His research interests center on clinical drug development for plasma cell disorders, healthcare disparities, and the biological variability of these diseases among ethnic minorities. Dr. Ailawadhi is fluent in English and is committed to advancing equitable cancer care through both clinical practice and research.
Affiliations and expertise
Mayo Clinic, USA